Cardiac medication was started in 146 (54.7%): beta‐blockers (n = 137, 51.3%); diuretics (n = 39, 14.6%); heart failure therapy including angiotensin‐converting enzyme inhibitors (ACE‐I) and diuretics (n = 9, 3.4%); anti‐arrhythmics (n = 3, 1.1%); disopyramide (n = 2, 0.7%); and calcium channel blockers (n = 1, 0.4%). This evidence concerns the gene ACE and heart failure.